Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TREH | O43280 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | PYGB | P11216 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11446120 | 1.00 | LGALS3 (0.42) | LGALS3LGALS1LGALS9LGALS8LMNA | |
| SCHEMBL6672320 | 0.86 | LGALS3 (0.36) | LGALS3LGALS1LGALS9LGALS8LMNA | |
| SCHEMBL7208163 | 0.84 | — | — | |
| SCHEMBL1864487 | 0.84 | — | — | |
| SCHEMBL7207613 | 0.84 | — | — | |
| SCHEMBL28138886 | 0.80 | — | — | |
| 1,5-Anhydrosorbitol SCHEMBL23026253 | 0.78 | LGALS3 (0.48) | LGALS3LGALS1LGALS9LGALS8LMNA | |
| 1,5-Anhydrosorbitol SCHEMBL21082117 | 0.78 | LGALS3 (0.48) | LGALS3LGALS1LGALS9LGALS8LMNA | |
| 1,5-Anhydrosorbitol SCHEMBL2280560 | 0.78 | LGALS3 (0.48) | LGALS3LGALS1LGALS9LGALS8LMNA | |
| 1,5-Anhydrosorbitol SCHEMBL20714515 | 0.78 | LGALS3 (0.48) | LGALS3LGALS1LGALS9LGALS8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5709737-A | AQUEOUS LIQUID VEHICLE, COLORANT, ALCOHOL ADDITIVE; SUITABLE FOR MICROWAVE DRYING PROCESSES | XEROX CORPORATION (US) | 1998-01-20 | — | — | US | claimed |
| US-20110268822-A1 | METHODS FOR SYNTHESIZING KOTALANOL AND STEREOISOMERS AND ANALOGUES THEREOF, AND NOVEL COMPOUNDS PRODUCED THEREBY | SIMON FRASER UNIVERSITY (CA) | 2011-11-03 | — | — | US | disclosed |
| EP-2274293-A1 | METHODS FOR SYNTHESIZING KOTALANOL AND STEREOISOMERS AND ANALOGUES THEREOF, AND NOVEL COMPOUNDS PRODUCED THEREBY | SIMON FRASER UNIVERSITY (CA) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009117829-A1 | METHODS FOR SYNTHESIZING KOTALANOL AND STEREOISOMERS AND ANALOGUES THEREOF, AND NOVEL COMPOUNDS PRODUCED THEREBY | SIMON FRASER UNIVERSITY (CA) | 2009-10-01 | — | — | WO | disclosed |
| US-20040138057-A1 | Catalyst composition and methods for its preparation and use in a polymerization process | WENZEL TIMOTHY T (US) | 2004-07-15 | — | — | US | disclosed |
| US-6566538-B1 | Preparation of 5-(aryloxymethyl)-g-butyrolactone derivatives | MILLENNIUM PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| EP-1094805-A4 | SUBSTITUTED OXYGEN ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | MILLENNIUM PHARM INC (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6433197-B1 | REACTING ARYLHYDROXY COMPOUND AND AN EPOXY COMPOUND TO FORM AN EPOXY-ARYL ETHER; REACTING EPOXY-ARYL ETHER WITH ACTIVE METHYLENE COMPOUND TO FORM A LACTONE; REDUCING TO PROVIDE HYDROXY-SUBSTITUTED TETRAHYDROFURAN | MILLENNIUM PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020040154-A1 | Substituted oxygen alicyclic compounds, including methods for synthesis thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2002-04-04 | — | — | US | disclosed |
| US-20020035278-A1 | Methods for synthesis of substituted tetrahydrofuran compound | MILLENNIUM PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |
| US-6310221-B1 | PREPARING A 4-FLUOROPHENOXYMETHYL-(HYDROXY)-TETRAHYDROFURAN BY REACTING 4-FLUOROPHENOL AND AN EPOXY COMPOUND; REACTING THE EPOXY-PHENYL ETHER WITH AN ACTIVE METHYLENE COMPOUND TO FORM A LACTONE; AND REDUCING THE LACTONE | MILLENNIUM PHARMACEUTICALS, INC. | 2001-10-30 | — | — | US | disclosed |
| US-6306895-B1 | PREPARATION OF CYCLIC OXYGEN COMPOUNDS, INCLUDING 2,5-DISUBSTITUTED TETAHYDROFURANS, 2,6-DISUBSTITUTED TETRAHYDROPYRANS, 2,7-DISUBSTITUTED OXEPANES AND 2,8-OXOCANES. THE INVENTION ALSO PROVIDES NEW CYCLIC OXYGEN COMPOUNDS AND | MILLENIUM PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1102759-A1 | METHODS FOR SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2001-05-30 | — | — | EP | disclosed |
| EP-1094805-A1 | SUBSTITUTED OXYGEN ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000001381-A1 | SUBSTITUTED OXYGEN ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | LEUKOSITE, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-2000001683-A1 | METHODS FOR SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN COMPOUND | LEUKOSITE, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| US-5709737-A | AQUEOUS LIQUID VEHICLE, COLORANT, ALCOHOL ADDITIVE; SUITABLE FOR MICROWAVE DRYING PROCESSES | XEROX CORPORATION (US) | 1998-01-20 | — | — | US | disclosed |
| US-4801710-A | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO., INC. (US) | 1989-01-31 | — | — | US | disclosed |
| US-4777293-A | Method for the synthesis of pharmacologically active compounds and intermediates for such synthesis | AKTIEBOLAGET HASSLE (SE) | 1988-10-11 | — | — | US | disclosed |
| EP-0184473-A1 | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO. INC. (US) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035278-A1 | Methods for synthesis of substituted tetrahydrofuran compound | DHFR, CYP3A4, CYP3A5 | LGALS3 4347/4885LGALS1 4728/4885LGALS9 4598/4885 |
| US-20020040154-A1 | Substituted oxygen alicyclic compounds, including methods for synthesis thereof | OXER1, COX6C, MT-CO2 | LGALS3 2679/4885LGALS1 2341/4885LGALS9 3158/4885 |
| US-20110268822-A1 | METHODS FOR SYNTHESIZING KOTALANOL AND STEREOISOMERS AND ANALOGUES THEREOF, AND NOVEL COMPOUNDS PRODUCED THEREBY | STS, LSS, CYP51A1 | LGALS3 962/4885LGALS1 1041/4885LGALS9 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.